Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. 1996

M K Danks, and K E Garrett, and R C Marion, and D O Whipple
Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101, USA.

DNA topoisomerase I is the cytotoxic target for chemotherapeutic agents of the camptothecin class. The cytotoxicity of these drugs is thought to be mediated by a dose-dependent increase in topoisomerase I molecules bound to DNA, resulting in DNA damage and cell death. We observed that in SJ-G5 human anaplastic astrocytoma cells growing in culture, the maximum number of topoisomerase I-DNA complexes occurred 5-15 min after the addition of 0.25-25 microM 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan; TPT) or 5 microM 7-ethyl-10-hydroxycamptothecin (SN-38). We postulated that the decline in number of complexes seen after 15 min might be due to decreases in the amount of topoisomerase I or the redistribution of this enzyme such that it could no longer bind to DNA. To investigate these possibilities, we incubated SJ-G5 cells for 20-60 min with 0.25-5 microM TPT and analyzed the cells for amount and localization of topoisomerase I by indirect immunofluorescence staining and fluorescence digital imaging microscopy. We verified the results obtained with fluorescence digital imaging microscopy by rapid fractionation of nuclear and cytoplasmic proteins, separation of these proteins by polyacrylamide gel electrophoresis, and densitometric scanning of immunoblots. Results showed that topoisomerase I dissociated from nucleoli within 60 min after treatment with 1-5 microM TPT. A small (25%) but significant (P < 0.05) decrease in the amount of nuclear topoisomerase I was also observed during this time course. Simultaneously, the cytoplasmic content of the Mr 67,000 form of topoisomerase I increased 50-100%. Preincubation of cells with 10 microM cycloheximide for 10 min prevented the increase of topoisomerase I in the cytoplasm, indicating that the increase was due, at least in part, to de novo protein synthesis. Interestingly, chemotherapeutic agents other than camptothecins were also found to dissociate topoisomerase I from nucleoli. These agents included m-AMSA (4'-(9-acridinylamino)methanesulfon-m-anisidide), mitoxantrone, actinomycin D, and daunorubicin. Drugs such as 1-beta-D-arabinofuranosylcytosine or hydroxyurea, which have no effect on RNA synthesis, did not induce the translocation. The biological significance of the ability of camptothecins to redistribute their own drug target is under investigation.

UI MeSH Term Description Entries
D008856 Microscopy, Fluorescence Microscopy of specimens stained with fluorescent dye (usually fluorescein isothiocyanate) or of naturally fluorescent materials, which emit light when exposed to ultraviolet or blue light. Immunofluorescence microscopy utilizes antibodies that are labeled with fluorescent dye. Fluorescence Microscopy,Immunofluorescence Microscopy,Microscopy, Immunofluorescence,Fluorescence Microscopies,Immunofluorescence Microscopies,Microscopies, Fluorescence,Microscopies, Immunofluorescence
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003593 Cytoplasm The part of a cell that contains the CYTOSOL and small structures excluding the CELL NUCLEUS; MITOCHONDRIA; and large VACUOLES. (Glick, Glossary of Biochemistry and Molecular Biology, 1990) Protoplasm,Cytoplasms,Protoplasms
D004264 DNA Topoisomerases, Type I DNA TOPOISOMERASES that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. DNA Topoisomerases, Type I enzymes reduce the topological stress in the DNA structure by relaxing the superhelical turns and knotted rings in the DNA helix. DNA Nicking-Closing Protein,DNA Relaxing Enzyme,DNA Relaxing Protein,DNA Topoisomerase,DNA Topoisomerase I,DNA Topoisomerase III,DNA Topoisomerase III alpha,DNA Topoisomerase III beta,DNA Untwisting Enzyme,DNA Untwisting Protein,TOP3 Topoisomerase,TOP3alpha,TOPO IIIalpha,Topo III,Topoisomerase III,Topoisomerase III beta,Topoisomerase IIIalpha,Topoisomerase IIIbeta,DNA Nicking-Closing Proteins,DNA Relaxing Enzymes,DNA Type 1 Topoisomerase,DNA Untwisting Enzymes,DNA Untwisting Proteins,Topoisomerase I,Type I DNA Topoisomerase,III beta, Topoisomerase,III, DNA Topoisomerase,III, Topo,III, Topoisomerase,IIIalpha, TOPO,IIIalpha, Topoisomerase,IIIbeta, Topoisomerase,Topoisomerase III, DNA,Topoisomerase, TOP3,beta, Topoisomerase III
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

M K Danks, and K E Garrett, and R C Marion, and D O Whipple
June 1998, Experimental cell research,
M K Danks, and K E Garrett, and R C Marion, and D O Whipple
March 1997, Blood,
M K Danks, and K E Garrett, and R C Marion, and D O Whipple
May 1995, Cancer research,
M K Danks, and K E Garrett, and R C Marion, and D O Whipple
January 2001, Molekuliarnaia biologiia,
M K Danks, and K E Garrett, and R C Marion, and D O Whipple
January 2003, Biopolymers,
M K Danks, and K E Garrett, and R C Marion, and D O Whipple
January 1996, Cancer practice,
M K Danks, and K E Garrett, and R C Marion, and D O Whipple
January 1994, Cancer treatment reviews,
M K Danks, and K E Garrett, and R C Marion, and D O Whipple
June 2014, Cytometry. Part A : the journal of the International Society for Analytical Cytology,
M K Danks, and K E Garrett, and R C Marion, and D O Whipple
March 1998, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!